Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
Authors:
- Andrea Ghelli Luserna Di RoràAndrea Ghelli Luserna Di Rorà
- Matteo BocconcelliMBMatteo Bocconcelli
- Anna FerrariAFAnna Ferrari
- Carolina TerragnaCarolina Terragna
- Samantha BrunoSBSamantha Bruno
- Enrica ImbrognoEIEnrica Imbrogno
- Neil BeeharryNBNeil Beeharry
- Valentina RobustelliVRValentina Robustelli
- Martina GhettiMGMartina Ghetti
- Roberta NapolitanoRNRoberta Napolitano
- Gabriella ChirumboloGCGabriella Chirumbolo
- Giovanni MarconiGMGiovanni Marconi
Open Access
Abstract
Introduction: Screening for synthetic lethality markers has demonstrated that the inhibition of the cell cycle checkpoint kinases WEE1 together with CHK1 drastically affects stability of the cell cycle and induces cell death in rapidly proliferating cells. Exploiting this finding for a possible therapeutic approach has showed efficacy in various solid and hematologic tumors, though not specifically tested in acute lymphoblastic leukemia. Methods: The efficacy of the combination between WEE1 and CHK1 inhibitors in B and T cell precursor acute lymphoblastic leukemia (B/T-ALL) was evaluated in vitro and ex vivo studies. The efficacy of the therapeutic strategy was tested in terms of cytotoxicity, induction of apoptosis, and changes in cell cycle profile and protein expression using B/T-ALL cell lines. In addition, the efficacy of the drug combination was studied in primary B-ALL blasts using clonogenic assays. Results: This study reports, for the first time, the efficacy of the concomitant inhibition of CHK1/CHK2 and WEE1 in ALL cell lines and primary leukemic B-ALL cells using two selective inhibitors: PF-0047736 (CHK1/CHK2 inhibitor) and AZD-1775 (WEE1 inhibitor). We showed strong synergism in the reduction of cell viability, proliferation and induction of apoptosis. The efficacy of the combination was related to the induction of early S-phase arrest and to the induction of DNA damage, ultimately triggering cell death. We reported evidence that the efficacy of the combination treatment is independent from the activation of the p53-p21 pathway. Moreover, gene expression analysis on B-ALL primary samples showed that Chek1 and Wee1 are significantly co-expressed in samples at diagnosis (Pearson r = 0.5770, p = 0.0001) and relapse (Pearson r= 0.8919; p = 0.0001). Finally, the efficacy of the combination was confirmed by the reduction in clonogenic survival of primary leukemic B-ALL cells. Conclusion: Our findings suggest that the combination of CHK1 and WEE1 inhibitors may be a promising therapeutic strategy to be tested in clinical trials for adult ALL.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (19226)
- National Institutes of Health (CA191956, CA006927, DoD W81XWH-17-1-0136)
- Associazione Italiana Contro le Leucemie - Linfomi e Mieloma (1)
- Fondazione del Monte di Bologna e Ravenna (ID ROL: FdM/6411)
This publication has 59 references indexed in Scilit:
- Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibitionCancer Cell International, 2012
- Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replicationNucleic Acids Research, 2011
- Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonucleaseJournal of Cell Biology, 2011
- Claspin and Chk1 regulate replication fork stability by different mechanismsCell Cycle, 2009
- Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTENMolecular Cancer Therapeutics, 2008
- ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA DamageScience, 2007
- Evidence That the ATR/Chk1 Pathway Maintains Normal Replication Fork Progression during Unperturbed S PhaseCell Cycle, 2006
- Distinct roles for cyclins E and A during DNA replication complex assembly and activationNature Cell Biology, 2002
- ATR Is Not Required for p53 Activation but Synergizes with p53 in the Replication CheckpointJournal of Biological Chemistry, 2002
- Rapid Destruction of Human Cdc25A in Response to DNA DamageScience, 2000